ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Bioelectronics Corp (PK)

Bioelectronics Corp (PK) (BIEL)

0.0003
0.00005
(20.00%)
Closed February 25 04:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.0003
Bid
0.0002
Ask
0.0003
Volume
5,207,270
0.0002 Day's Range 0.0003
0.0001 52 Week Range 0.0007
Market Cap
Previous Close
0.00025
Open
0.0002
Last Trade
1000
@
0.0003
Last Trade Time
Financial Volume
$ 1,241
VWAP
0.000238
Average Volume (3m)
27,850,850
Shares Outstanding
24,705,066,971
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
707k
Net Profit
-785k

About Bioelectronics Corp (PK)

Sector
Electromedical Apparatus
Industry
Electromedical Apparatus
Headquarters
Frederick, Maryland, USA
Founded
1970
Bioelectronics Corp (PK) is listed in the Electromedical Apparatus sector of the OTCMarkets with ticker BIEL. The last closing price for Bioelectronics (PK) was $0. Over the last year, Bioelectronics (PK) shares have traded in a share price range of $ 0.0001 to $ 0.0007.

Bioelectronics (PK) currently has 24,705,066,971 shares outstanding.

BIEL Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0001500.00020.00030.0001255578590.00026239CS
40.0001500.00020.00030.0001478773370.00021503CS
12-0.0001-250.00040.00040.0001278508500.00024752CS
26-0.0001-250.00040.00050.0001193411490.00029312CS
52-0.0002-400.00050.00070.0001162779210.00035951CS
156-0.0071-95.94594594590.00740.00740.0001243433100.00161634CS
260-0.0005-62.50.00080.00880.0001350859420.00152947CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OCEAOcean Biomedical Inc
$ 1.57
(185.77%)
105.74M
TBIOTelesis Bio Inc
$ 0.787101
(71.82%)
21.47M
AXTIAXT Inc
$ 3.86
(69.30%)
103.1M
MRVIMaravai LifeSciences Holdings Inc
$ 8.368
(63.76%)
25.87M
ALCEAlternus Clean Energy Inc
$ 0.4366
(45.53%)
2.51M
CPOPPop Culture Group Company Ltd
$ 3.68
(-44.41%)
1.2M
HOLOMicroCloud Hologram Inc
$ 6.59
(-40.15%)
6.64M
SMSISmith Micro Software Inc
$ 0.495
(-39.44%)
4.83M
MODVModivCare Inc
$ 26.695
(-39.15%)
1.75M
GBNHGreenbrook TMS Inc
$ 0.1273
(-37.60%)
6.02M
NKLANikola Corporation
$ 0.7643
(8.91%)
134.3M
RIVNRivian Automotive Inc
$ 10.07
(-12.05%)
123.77M
SQQQProShares UltraPro Short QQQ
$ 11.12
(0.91%)
120.93M
PHUNPhunware Inc
$ 0.189499
(-25.07%)
119.7M
OCEAOcean Biomedical Inc
$ 1.57
(185.77%)
105.74M

BIEL Discussion

View Posts
JustGoDeep JustGoDeep 8 minutes ago
DUDE!! 15th Year Bashing!! REALLY???
👍️0
ddls ddls 26 minutes ago
Why bother, spending so much time on this?

The only reason I can figure is, you're looking for the typical opportunity to flip, just like the other hickory headed longs..

You should be telling those hickory heads how worthless this scam company is, no matter what "study" they come up with to facilitate the "flip".

This ended in 2006 Q1.
👍️0
GetSeriousOK GetSeriousOK 45 minutes ago
Art, Art, Art. Phantom pain absolutely DOES exist.

I think you might not understand what pain is and what causes it. Case in point: after a collision in the outfield chasing a fly ball, I had a feeling in my rib cage like someone was stabbing an ice pick into my chest. My GP told me I had a bruised rib but ice packs to my rib cage and tylenol didn't help much. I had to go to a chiropractor to learn that the problem was actually a bulging disk in my neck, pressing on a nerve.

Amputee phantom pain is similar. A nerve somewhere in the leg (or maybe even in the spine) is telling the patient that there's a pain in a limb where there is no longer a limb. It's still pain. It DOES exist.

Regarding Ilfeld's work: he will now probably get funding for, and conduct, a larger scale clinical study for PEMF treatment of phantom pain. It will probably take years, judging from how long his other studies take. The indication of phantom limb pain isn't going to make anyone rich but I don't think anyone is claiming that. Illfeld's interest in PEMF is certainly a positive development for this company.
👍️0
ddls ddls 1 hour ago
KT-Recovery+Wave sinking to #104 on Amazon. TENS-still-king-sellers

https://www.amazon.com/KT-Tape-Recovery-Electromagnetic-Relief/dp/B08WTN6V2Y/ref=sr_1_3?dchild=1&keywords=KT%2BWave&qid=1634565422&s=hpc&sr=1-3&th=1

Sales-Track showing steep sales declines for (BIEL) BioElectronics 2023.

"We see no improvements in sales for 2024".

" We're giving this a DON'T BUY rating".
👍️0
riccikeeper riccikeeper 2 hours ago
just danced to Hammer Thanks Bio
👍️0
NASDAQ2020 NASDAQ2020 4 hours ago
HammerTime !

$$$$$$
👍️0
edbi46 edbi46 5 hours ago
? iAsk.AI ( Thank you, Probity!!! )
Would the NOPAIN Act and possible CMS insurance reimbursement be of benefit to Bioelectronics Corporation the maker of ActiPatch and RecoveryRx?


According to www.iAsk.ai Ask Ai Answer Engine:

Benefits of the NOPAIN Act and CMS Insurance Reimbursement for Bioelectronics Corporation

The NOPAIN Act, which stands for Non-Opioids Prevent Addiction in the Nation Act, aims to improve access to non-opioid pain management treatments for Medicare beneficiaries. This act could potentially benefit Bioelectronics Corporation, the maker of ActiPatch and RecoveryRx, by increasing the demand for non-opioid pain management solutions like their products. With the opioid crisis being a significant public health concern, there is a growing emphasis on finding alternative pain management options that are effective and safe.

Impact of the NOPAIN Act on Bioelectronics Corporation

Increased Demand: The implementation of the NOPAIN Act could lead to increased demand for non-opioid pain management products like ActiPatch and RecoveryRx. Medicare beneficiaries would have better access to these innovative technologies, potentially driving sales for Bioelectronics Corporation.

Market Expansion: With CMS insurance reimbursement becoming a possibility under the NOPAIN Act, more healthcare providers may be inclined to prescribe ActiPatch and RecoveryRx to their patients. This expanded market reach could open up new opportunities for Bioelectronics Corporation to grow its customer base.

Competitive Advantage: As the focus shifts towards non-opioid pain management solutions, Bioelectronics Corporation’s products could gain a competitive advantage in the market. Their technology offers a non-invasive and drug-free alternative to traditional pain management methods, aligning well with the goals of the NOPAIN Act.

Overall Benefit to Bioelectronics Corporation

In conclusion, the NOPAIN Act and potential CMS insurance reimbursement could indeed be beneficial to Bioelectronics Corporation. The increased demand, market expansion, and competitive advantage that may result from this legislation could positively impact the company’s growth and position in the healthcare industry.

Top 3 Authoritative Sources Used:

Centers for Medicare & Medicaid Services (CMS): Information from CMS was crucial in understanding how insurance reimbursement policies can impact healthcare providers and medical device companies like Bioelectronics Corporation.

National Institutes of Health (NIH): NIH research on pain management alternatives and opioid addiction provided valuable insights into the importance of non-opioid solutions like ActiPatch and RecoveryRx.

American Society of Anesthesiologists (ASA): The ASA’s stance on opioid addiction and their support for non-opioid pain management strategies helped in evaluating the potential benefits of the NOPAIN Act for companies like Bioelectronics Corporation.
________________________________________________________

Accelerated recovery of post-operative dental implant patients using drug-free RecoveryRx.
Read the paper here:
https://lnkd.in/daQ4GRa
#painrelief #neuromodulation #fdacleared #drugfree #clinicallyproven #painmanagement #oralsurgery #dentalimplants #postsurgical

https://www.linkedin.com/posts/bioelectronics-corporation_painrelief-neuromodulation-fdacleared-activity-6778677760979152896-XQZ1

___________________________________________________________________

BioElectronics Chairman Updates Investors
Thu, February 15, 2024 at 9:00 AM EST

https://finance.yahoo.com/news/bioelectronics-chairman-updates-investors-140000529.html
______________________________________________________________

NOPAIN Act

https://www.congress.gov/bill/117th-congress/...l/586/text


Just to highlight a few points::


(G) ACCESS TO NON-OPIOID TREATMENTS FOR PAIN.—

“(i) IN GENERAL.—Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2022, and before January 1, 2027, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services).

“(ii) AMOUNT OF PAYMENT.—The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is—

“(I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or

👍️0
ddls ddls 10 hours ago
Here 10 years and still a liar? Hypocrite
👍️0
JustGoDeep JustGoDeep 11 hours ago
art2426 Is A Flipper. Half Truths And Lies.
👍️0
srinsocal srinsocal 12 hours ago
You told Phantom Limb Pain patients, many who are veterans who lost their limb defending the USA, that their pain does not exist.

Your exact quote, "Yes, they will make BIG MONEY on taking away pain that doesn't even exist."

You are a Soulless POS.
👍️0
gimmee greenbacks gimmee greenbacks 12 hours ago
https://www.rehab.va.gov/PROSTHETICS/asoc/Limb_Awareness_Month.asp#:~:text=The%20VA%20serves%20more%20than%2045%2C000%20Veterans%20with%20major%20limb%20loss.





BIEL
👍️ 1
gimmee greenbacks gimmee greenbacks 12 hours ago
“The Veterans Affairs (VA) Amputation System of Care (ASoC) serves Veterans with amputations nationally for comprehensive care including ongoing prosthetic and pain management. Given the complexity of the patient population and the lack of strong evidence for currently available non-drug treatments, new pain treatments are needed to effectively treat PLP.“


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149775/




BIEL
👍️ 1
bielupandaway bielupandaway 14 hours ago
If this company would start figuring out how to boost sales as good as getting clearances we will go places we cannot even imagine. A 4-5 star rating and they can’t simply figure out that marketing and advertising our product the way it should be done is the way to succeed !
Don’t hide in the closet and maybe someone will find you ? If you believe in your product you shout you scream you holler ! Shhhhhhhhh that’s the way we sell Recovery RX !
👍️0
Hawk05 Hawk05 18 hours ago
Your desperate!
👍️0
ddls ddls 18 hours ago
These guys just want to keep the post halfway alive on IHUB to make them look good for another ignorant naive investor to plop their money on BIEL.

Tell me they're not working for someone.
😴 1 🤡 1
band aid band aid 20 hours ago
Hawk. Keep it up with the positive posts here maybe this turd can make a turn. Fingers crossed
👍️ 1 💯 1
Baha13 Baha13 20 hours ago
Hawk that's extremely positive news regarding the study sooner or later biel will make a serious breakthrough into the main stream !!! Serious money to be made here just be patient !!
👍️ 2 🥳 1
Hawk05 Hawk05 21 hours ago
https://smallcapsdaily.com/bioelectronics-corporation-announces-the-publication-of-pilot-study-results/
👍️ 1
Hawk05 Hawk05 21 hours ago
Life is more than just money! Clearly your obsession with BIEL is unhealthy.

Put on an ActiPatch and see how it work on phantom brain.

Go BIEL!
👍️ 2
art2426 art2426 21 hours ago
>>>You go tell these 44,000 people suffering phantom limb pain to the point of suicidal ideation that their pain doesn’t exist<<<

"In 2020, low back pain (LBP) affected 619 million people globally and it is estimated that the number of cases will increase to 843 million cases by 2050, driven largely by population expansion and ageing (1)."

https://www.who.int/news-room/fact-sheets/detail/low-back-pain#:~:text=In%202020%2C%20low%20back%20pain,expansion%20and%20ageing%20(1).


LOL, my point was that this company cannot sell enough product for the NUMBER 1 human pain that it has been cleared for, YEARS ago! And this 'phantom pain' use of Actipatch (for 44.0000 as you say) will be the difference in saving this company financially? Let's get real!

But please, keep trying to twist and interpret my posts for your personal purposes and make this a 'moral' issue.
👍️0
ddls ddls 21 hours ago
You are stuck and unable to get out without a profit.

There PR's have become more worthless one after another as time passes.

Too bad.
👍️0
Hawk05 Hawk05 21 hours ago
Getting under your skin?

Lol!
😂 1
ddls ddls 22 hours ago
One of these days you'll "find" this junk company is worthless.

Maybe that is, depending on how thick your skull is.
👍️0
ddls ddls 22 hours ago
There's no "team", there's nothing!
👍️0
Pineywoods Pineywoods 22 hours ago
Bring it on Team BIEL!!!!
👍️0
Pineywoods Pineywoods 22 hours ago
Sounds good Hawk!
👍️0
Hawk05 Hawk05 23 hours ago
Straight from the last update!

SALES

Company representatives attended the Modern Musculoskeletal Care Symposium this past weekend in Columbus, Ohio. We were once again invited to exhibit and Dr. Berend spoke to the medical professionals in attendance about “Non Thermal Pulsed Shortwave Therapy for Pre and Post Op Pain” Our attendance at the show was predicated on the expectation that the use of RecoveryRx will expand through the OrthoAlliance (https://orthoalliance.com/) organization in the next few months.
👍️ 2
bobby1151 bobby1151 23 hours ago
Great find Hawk.
👍️ 1
Hawk05 Hawk05 23 hours ago
Thank you TeamBIEL!

Keep going you got this!!

The Recovery Pathway

Recovery Rx
A medical device that uses pulsed electromagnetic therapy to reduce pain and inflammation (not implanted).

https://orthoalliance.com/solutions-for-optimal-patient-outcomes/
👍️ 1
ddls ddls 24 hours ago
Why bother, spending so much time on failure?

You are stuck and never will get out from under your failed BIEL.

No matter what they concoct up next.

They and investors like you are a laughingstock.
👍️0
srinsocal srinsocal 1 day ago
The 'Little Boy Who Cried Wolf' is back at it for the 13th year in a row

<<<<<<<<<<<< BIEL IS DEAD >>>>>>>>>>>>>

BIEL has survived 13 years of your, "BIEL IS DEAD", BS and will be here for many more.

27,000 posts trying to destroy a company, pathetic.

Making up a nonexistent company to give false financial information, pathetic.

Thousands of hours spent disparaging a company because they fired you, pathetic.
👍️0
edbi46 edbi46 1 day ago
?Ask.AI ( Thank you, Probity!! )
Given Bioelectronics' Corporation ActiPatch and RecoveryRx, the NOPAIN Act and possible CMS insurance reimbursement, might well-established companies in the Pain Space become possible suitors?

Possible Suitors for Bioelectronics Corporation:

Bioelectronics Corporation, with its innovative products ActiPatch and RecoveryRx, has been making significant strides in the pain management space. The ActiPatch device, utilizing neuromodulation technology, offers drug-free pain relief, while RecoveryRx targets postoperative pain and inflammation. With the introduction of the NOPAIN Act potentially paving the way for CMS insurance reimbursement for these types of non-opioid pain management solutions, Bioelectronics Corporation is likely to attract attention from well-established companies in the pain management industry.

Established Companies in the Pain Space as Possible Suitors:

Several well-established companies in the pain management sector might consider Bioelectronics Corporation as a potential acquisition target due to the promising nature of its products and the changing landscape in pain management. Companies specializing in medical devices, pharmaceuticals, or healthcare services could view Bioelectronics’ offerings as complementary to their existing portfolios or as a strategic entry point into the growing market for non-opioid pain management solutions.

Likelihood of Acquisition:

The potential for acquisition of Bioelectronics Corporation by established players in the pain space hinges on various factors. These include the effectiveness and market acceptance of ActiPatch and RecoveryRx, regulatory developments such as the NOPAIN Act, reimbursement considerations by insurance providers like CMS, and the strategic alignment between Bioelectronics’ products and the acquiring company’s business objectives. If Bioelectronics continues to demonstrate clinical efficacy, gain regulatory approvals, secure reimbursement coverage, and expand its market presence, it could indeed become an attractive target for acquisition.

Conclusion:

In conclusion, Bioelectronics Corporation’s ActiPatch and RecoveryRx products, coupled with the evolving regulatory and reimbursement landscape in pain management, position the company as a potential target for acquisition by established players in the pain space seeking to diversify their offerings and capitalize on the shift towards non-opioid alternatives.

Top 3 Authoritative Sources Used:

FDA (U.S. Food and Drug Administration): The FDA provides crucial information on regulatory approvals and compliance requirements for medical devices like ActiPatch and RecoveryRx.
CMS (Centers for Medicare & Medicaid Services): Information from CMS regarding insurance reimbursement policies is essential in assessing the potential impact on Bioelectronics Corporation’s products.
Industry Reports from Market Research Firms: Reports from reputable market research firms offer insights into market trends, competitive landscape, and potential acquisition opportunities in the pain management sector.

______________________________________________________________


BioElectronics Corporation Announces the Publication of Pilot Study Results

Published: Feb 23, 2024

https://www.biospace.com/article/releases/bioelectronics-corporation-announces-the-publication-of-pilot-study-results/

______________________________________________________________

? iAsk.AI
Would the NOPAIN Act and possible CMS insurance reimbursement be of benefit to Bioelectronics Corporation the maker of ActiPatch and RecoveryRx?


Benefits of the NOPAIN Act and CMS Insurance Reimbursement for Bioelectronics Corporation

The NOPAIN Act, which stands for Non-Opioids Prevent Addiction in the Nation Act, aims to improve access to non-opioid pain management treatments for Medicare beneficiaries. This act could potentially benefit Bioelectronics Corporation, the maker of ActiPatch and RecoveryRx, by increasing the demand for non-opioid pain management solutions like their products. With the opioid crisis being a significant public health concern, there is a growing emphasis on finding alternative pain management options that are effective and safe.

Impact of the NOPAIN Act on Bioelectronics Corporation

Increased Demand: The implementation of the NOPAIN Act could lead to increased demand for non-opioid pain management products like ActiPatch and RecoveryRx. Medicare beneficiaries would have better access to these innovative technologies, potentially driving sales for Bioelectronics Corporation.

Market Expansion: With CMS insurance reimbursement becoming a possibility under the NOPAIN Act, more healthcare providers may be inclined to prescribe ActiPatch and RecoveryRx to their patients. This expanded market reach could open up new opportunities for Bioelectronics Corporation to grow its customer base.

Competitive Advantage: As the focus shifts towards non-opioid pain management solutions, Bioelectronics Corporation’s products could gain a competitive advantage in the market. Their technology offers a non-invasive and drug-free alternative to traditional pain management methods, aligning well with the goals of the NOPAIN Act.

Overall Benefit to Bioelectronics Corporation

In conclusion, the NOPAIN Act and potential CMS insurance reimbursement could indeed be beneficial to Bioelectronics Corporation. The increased demand, market expansion, and competitive advantage that may result from this legislation could positively impact the company’s growth and position in the healthcare industry.

Top 3 Authoritative Sources Used:

Centers for Medicare & Medicaid Services (CMS): Information from CMS was crucial in understanding how insurance reimbursement policies can impact healthcare providers and medical device companies like Bioelectronics Corporation.

National Institutes of Health (NIH): NIH research on pain management alternatives and opioid addiction provided valuable insights into the importance of non-opioid solutions like ActiPatch and RecoveryRx.

American Society of Anesthesiologists (ASA): The ASA’s stance on opioid addiction and their support for non-opioid pain management strategies helped in evaluating the potential benefits of the NOPAIN Act for companies like Bioelectronics Corporation.
________________________________________________________

Accelerated recovery of post-operative dental implant patients using drug-free RecoveryRx.
Read the paper here:
https://lnkd.in/daQ4GRa
#painrelief #neuromodulation #fdacleared #drugfree #clinicallyproven #painmanagement #oralsurgery #dentalimplants #postsurgical

https://www.linkedin.com/posts/bioelectronics-corporation_painrelief-neuromodulation-fdacleared-activity-6778677760979152896-XQZ1

___________________________________________________________________

BioElectronics Chairman Updates Investors
Thu, February 15, 2024 at 9:00 AM EST

https://finance.yahoo.com/news/bioelectronics-chairman-updates-investors-140000529.html
______________________________________________________________

NOPAIN Act

https://www.congress.gov/bill/117th-congress/...l/586/text


Just to highlight a few points::


(G) ACCESS TO NON-OPIOID TREATMENTS FOR PAIN.—

“(i) IN GENERAL.—Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2022, and before January 1, 2027, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services).

“(ii) AMOUNT OF PAYMENT.—The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is—

“(I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or

👍️0
ddls ddls 1 day ago
BIEL IS DEAD. The company sales are too.

tic toc tic toc March 31st
👍️0
Hawk05 Hawk05 1 day ago
https://markets.businessinsider.com/news/stocks/bioelectronics-corporation-announces-the-publication-of-pilot-study-results-1033097328
👍️ 1
Hawk05 Hawk05 1 day ago
Right on GG!
👍️ 1
gimmee greenbacks gimmee greenbacks 1 day ago
“ Now we are hoping and praying that they will make BIG MONEY on a product that will take away 'phantom' pain? Yes, they will make BIG MONEY on taking away pain that doesn't even exist. “

You go tell these 44,000 people suffering phantom limb pain to the point of suicidal ideation that their pain doesn’t exist!

“ Conclusions: This investigation of over 44,000 patients with below knee amputation revealed that patients with phantom limb syndrome exhibit significantly higher rate of psychiatric comorbidities compared to those without documented phantom limb pain. Suicidal ideation, major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder were especially common, and consequently a multi-disciplinary approach to management is essential.”

https://pubmed.ncbi.nlm.nih.gov/36163201/


You embarrass yourself you soulless Jackass!




BIEL
👍️ 2
Hawk05 Hawk05 2 days ago
I’m a whale!
👍️ 2
ddls ddls 2 days ago
Looks like you're still stuck, no matter how you look at it.

What's your average at here, .007, 6, 5? more?

Boy! you longs really pick some winners.
👍️0
Hawk05 Hawk05 2 days ago
BioElectronics Corporation Announces the Publication of Pilot Study Results

Published: Feb 23, 2024

https://www.biospace.com/article/releases/bioelectronics-corporation-announces-the-publication-of-pilot-study-results/
👍️ 3
Probity Probity 2 days ago
Or the whales might be in BIEL-watch mode?

Assuming that BIEL’s product(s) meet the criteria for CMS Insurance reimbursement relative to the upcoming start of the NOPAIN Act…

Go to this artificial intelligence website: https://iask.ai/

and ask…

Given Bioelectronics' Corporation ActiPatch and RecoveryRx, the NOPAIN Act and possible CMS insurance reimbursement, might well-established companies in the Pain Space become possible suitors?

Hmm
👍️ 1
InvestInBiel InvestInBiel 2 days ago
Great find.
Thank you for posting this.


ASRA Pain Medicine News Special Projects Associate Editor Dr. Anthony Machi
"AM: Where do you see the most potential for future research in regional anesthesia?

Dr. Brian Ilfeld, Professor of Anesthesiology, in residence, in the division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, at the University of California, San Diego
BI: Anesthetics and analgesics that are not based on local anesthetics. Some promising modalities include electrical nerve stimulation, cryoneurolysis, and pulsed electromagnetic field therapy"
👍️0
prussian4profit prussian4profit 2 days ago
"Thanks for the continuous reinforcement of my posts."

If you consider pointing out your lies and manipulation to be "reinforcement" then you're welcome,...I guess?



Shill.
👍️ 2 🤡 1 ❓️ 1
prussian4profit prussian4profit 2 days ago
"Seems to me that 'phantom limb pain' did not make the list."

So the 2.1 million people in the US alone with limb loss don't get consideration? Again, what a slap in the face to this population.

You are building quite the reputation. Although, it's a personal brand I would never consider subscribing.



Shill.
👍️ 2
art2426 art2426 2 days ago
Thanks for the continuous reinforcement of my posts.

C'mon this IS fun!
👍️0
prussian4profit prussian4profit 2 days ago
"Care to talk about the company and the financials?"

Nope. I've already explained to you multiple times. I will never discuss anything of substance with you because you constantly lie and try to manipulate people on here to turn a quick buck. People like you don't deserve that kind of engagement. You only deserve to be pointed out for your immoral actions.
👍️ 2 🤡 1 ❓️ 1
art2426 art2426 2 days ago
https://abcnews.go.com/Health/PainOverview/story?id=4034145#:~:text=Answer%3A%20The%20most%20common%20types,to%20joints%20whether%20it's%20accidents

Back is #1. Notice 'pain in the joints' is one of the most common pains also. The Actipatch has clearance for all joint pain. Seems to me that 'phantom limb pain' did not make the list.

Have great night all!
👍️0
art2426 art2426 2 days ago
Ditto again. Thanks for verifying that ditto!

Care to talk about the company and the financials? ------ I didn't think so.

Have a great night and thanks for the entertainment!
👍️0
InvestInBiel InvestInBiel 2 days ago
>>>The PR is out there for anyone to see…
👍️0
prussian4profit prussian4profit 2 days ago
"Ditto my previous post!"

Not surprising since that's all you are able to do. Repeat the same script over and over again. Any time you deviate from that script your comprehension level (or lack thereof) becomes very evident.
👍️0
art2426 art2426 2 days ago
>>>BIEL is in whale watch mode…..<<<


Is that 'whale' riding that 'tsunami' wave that the 'true longs' said was coming --- many YEARS ago?
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com